(Q52208202)

English

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM

scientific article published in August 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

author name string

Newby LK

1

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

language of work or name

0 references

publication date

1 August 1999

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

138

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

2 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

210-218

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

A randomized trial of aspirin and beta-carotene among U.S. physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Impaired platelet-connective-tissue reaction in man after aspirin ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Effects of salicylates on human platelets.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970104-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-8703(99)70104-3

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

release_tnq3kx2rrvedrloro2ygb4jy4y

1 reference

https://api.fatcat.wiki/v0/release/tnq3kx2rrvedrloro2ygb4jy4y

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 April 2018

http://europepmc.org/abstract/MED/10426831

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52208202&oldid=1842708401"